Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy

The ability of cocaine to inhibit the dopamine transporter (DAT) appears to be crucial for its reinforcing properties. The potential use of drugs that produce longlasting inhibition of the DAT as a mean of preventing the ``high'' and reducing drug-seeking behavior has become a major strate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 1996-09, Vol.93 (19), p.10388-10392
Hauptverfasser: Volkow, N. D., G.-J. Wang, Fowler, J. S., Gatley, S. J., Y.-S. Ding, Logan, J., Dewey, S. L., Hitzemann, R., Lieberman, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10392
container_issue 19
container_start_page 10388
container_title Proceedings of the National Academy of Sciences - PNAS
container_volume 93
creator Volkow, N. D.
G.-J. Wang
Fowler, J. S.
Gatley, S. J.
Y.-S. Ding
Logan, J.
Dewey, S. L.
Hitzemann, R.
Lieberman, J.
description The ability of cocaine to inhibit the dopamine transporter (DAT) appears to be crucial for its reinforcing properties. The potential use of drugs that produce longlasting inhibition of the DAT as a mean of preventing the ``high'' and reducing drug-seeking behavior has become a major strategy in medication development. However, neither the relation between the high and DAT inhibition nor the ability to block the high by prior DAT blockade have ever been demonstrated. To evaluate if DAT could prevent the high induced by methylphenidate (MP), a drug which like cocaine inhibits the DAT, we compared the responses in eight nondrug-abusing subjects between the first and the second of two MP doses (0.375 mg/kg, i.v.) given 60 min apart. At 60 min the high from MP has returned to baseline, but 75-80% of the drug remains in brain. Positron-emission tomography and [$^{11}$C]d-threo-MP were used to estimate DAT occupancies at different times after MP. DAT inhibition by MP did not block or attenuate the high from a second dose of MP given 60 min later, despite a 80% residual transporter occupancy from the first dose. Furthermore some subjects did not perceive a high after single or repeated administration despite significant DAT blockade. These results indicate that DAT occupancy is not sufficient to account for the high, and that for DAT inhibitors to be therapeutically effective, occupancies >80% may be required.
doi_str_mv 10.1073/pnas.93.19.10388
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_15843469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40395</jstor_id><sourcerecordid>40395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-bca3119d6915712db127d63755ae51772975c1d21a5d015df95bed62dc669f693</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxS0EKkvhjpAQUQ-ISxZPHH9JXFD5aKVKRaiIo-vYTjerxE5tB9j_niy7rCgHOI1G7_dGM_MQegp4CZiT16PXaSnJEuTcEyHuoQVgCSWrJb6PFhhXvBR1VT9Ej1JaY4wlFfgIHQkBTABeoK-fXa9zF3xadWPRuPzdOV98ShuzCil3w9Rrn8tzbyfjbHF9fdbdrE4K7W3xLox66LwrrqL2aQwxu1hcGjON2pvNY_Sg1X1yT_b1GH358P7q9Ky8uPx4fvr2ojS0IrlsjCYA0jIJlENlG6i4ZYRTqh0FzivJqQFbgaYWA7WtpI2zrLKGMdkySY7Rm93ccWoGZ43zOepejbEbdNyooDt1V_HdSt2Eb4oIIuvZ_nJvj-F2cimroUvG9fPVLkxJcUFqxgn7LwhU1DO6XejkL3AdpujnH6gKAwEpMZkhvINMDClF1x4WBqy2waptsEoSBVL9Cna2PP_z0INhn-Ssv9jrW-dv9e6EV_8mVDv1fXY_8ow-26HrlEM8sDUmkpKf0uTBcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201319903</pqid></control><display><type>article</type><title>Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Volkow, N. D. ; G.-J. Wang ; Fowler, J. S. ; Gatley, S. J. ; Y.-S. Ding ; Logan, J. ; Dewey, S. L. ; Hitzemann, R. ; Lieberman, J.</creator><creatorcontrib>Volkow, N. D. ; G.-J. Wang ; Fowler, J. S. ; Gatley, S. J. ; Y.-S. Ding ; Logan, J. ; Dewey, S. L. ; Hitzemann, R. ; Lieberman, J.</creatorcontrib><description>The ability of cocaine to inhibit the dopamine transporter (DAT) appears to be crucial for its reinforcing properties. The potential use of drugs that produce longlasting inhibition of the DAT as a mean of preventing the ``high'' and reducing drug-seeking behavior has become a major strategy in medication development. However, neither the relation between the high and DAT inhibition nor the ability to block the high by prior DAT blockade have ever been demonstrated. To evaluate if DAT could prevent the high induced by methylphenidate (MP), a drug which like cocaine inhibits the DAT, we compared the responses in eight nondrug-abusing subjects between the first and the second of two MP doses (0.375 mg/kg, i.v.) given 60 min apart. At 60 min the high from MP has returned to baseline, but 75-80% of the drug remains in brain. Positron-emission tomography and [$^{11}$C]d-threo-MP were used to estimate DAT occupancies at different times after MP. DAT inhibition by MP did not block or attenuate the high from a second dose of MP given 60 min later, despite a 80% residual transporter occupancy from the first dose. Furthermore some subjects did not perceive a high after single or repeated administration despite significant DAT blockade. These results indicate that DAT occupancy is not sufficient to account for the high, and that for DAT inhibitors to be therapeutically effective, occupancies &gt;80% may be required.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.93.19.10388</identifier><identifier>PMID: 8816810</identifier><language>eng</language><publisher>United States: National Academy of Sciences of the United States of America</publisher><subject>Adult ; Anxiety ; Blood plasma ; Blood Pressure - drug effects ; Brain - diagnostic imaging ; Brain - drug effects ; Brain - physiology ; Carbon Radioisotopes ; Carrier Proteins - drug effects ; Carrier Proteins - metabolism ; Central Nervous System Stimulants - pharmacokinetics ; Central Nervous System Stimulants - pharmacology ; Cerebellum ; Cerebellum - diagnostic imaging ; Cerebellum - drug effects ; Cerebellum - physiology ; Cocaine ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - drug effects ; Corpus Striatum - physiology ; Dopamine Plasma Membrane Transport Proteins ; Dopamine Uptake Inhibitors - pharmacokinetics ; Dopamine Uptake Inhibitors - pharmacology ; Dosage ; Drug therapy ; Emotions - drug effects ; Emotions - physiology ; Heart rate ; Heart Rate - drug effects ; Humans ; Kinetics ; Male ; Medical research ; Medications ; Membrane Glycoproteins ; Membrane Transport Proteins ; Methylphenidate - pharmacokinetics ; Methylphenidate - pharmacology ; Nerve Tissue Proteins ; Perception tests ; Positron emission tomography ; T tests ; Time Factors ; Tissue Distribution ; Tomography, Emission-Computed</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 1996-09, Vol.93 (19), p.10388-10392</ispartof><rights>Copyright 1996 National Academy of Sciences</rights><rights>Copyright National Academy of Sciences Sep 17, 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-bca3119d6915712db127d63755ae51772975c1d21a5d015df95bed62dc669f693</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/93/19.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40395$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40395$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27901,27902,53766,53768,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8816810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Volkow, N. D.</creatorcontrib><creatorcontrib>G.-J. Wang</creatorcontrib><creatorcontrib>Fowler, J. S.</creatorcontrib><creatorcontrib>Gatley, S. J.</creatorcontrib><creatorcontrib>Y.-S. Ding</creatorcontrib><creatorcontrib>Logan, J.</creatorcontrib><creatorcontrib>Dewey, S. L.</creatorcontrib><creatorcontrib>Hitzemann, R.</creatorcontrib><creatorcontrib>Lieberman, J.</creatorcontrib><title>Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>The ability of cocaine to inhibit the dopamine transporter (DAT) appears to be crucial for its reinforcing properties. The potential use of drugs that produce longlasting inhibition of the DAT as a mean of preventing the ``high'' and reducing drug-seeking behavior has become a major strategy in medication development. However, neither the relation between the high and DAT inhibition nor the ability to block the high by prior DAT blockade have ever been demonstrated. To evaluate if DAT could prevent the high induced by methylphenidate (MP), a drug which like cocaine inhibits the DAT, we compared the responses in eight nondrug-abusing subjects between the first and the second of two MP doses (0.375 mg/kg, i.v.) given 60 min apart. At 60 min the high from MP has returned to baseline, but 75-80% of the drug remains in brain. Positron-emission tomography and [$^{11}$C]d-threo-MP were used to estimate DAT occupancies at different times after MP. DAT inhibition by MP did not block or attenuate the high from a second dose of MP given 60 min later, despite a 80% residual transporter occupancy from the first dose. Furthermore some subjects did not perceive a high after single or repeated administration despite significant DAT blockade. These results indicate that DAT occupancy is not sufficient to account for the high, and that for DAT inhibitors to be therapeutically effective, occupancies &gt;80% may be required.</description><subject>Adult</subject><subject>Anxiety</subject><subject>Blood plasma</subject><subject>Blood Pressure - drug effects</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - drug effects</subject><subject>Brain - physiology</subject><subject>Carbon Radioisotopes</subject><subject>Carrier Proteins - drug effects</subject><subject>Carrier Proteins - metabolism</subject><subject>Central Nervous System Stimulants - pharmacokinetics</subject><subject>Central Nervous System Stimulants - pharmacology</subject><subject>Cerebellum</subject><subject>Cerebellum - diagnostic imaging</subject><subject>Cerebellum - drug effects</subject><subject>Cerebellum - physiology</subject><subject>Cocaine</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - physiology</subject><subject>Dopamine Plasma Membrane Transport Proteins</subject><subject>Dopamine Uptake Inhibitors - pharmacokinetics</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Dosage</subject><subject>Drug therapy</subject><subject>Emotions - drug effects</subject><subject>Emotions - physiology</subject><subject>Heart rate</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical research</subject><subject>Medications</subject><subject>Membrane Glycoproteins</subject><subject>Membrane Transport Proteins</subject><subject>Methylphenidate - pharmacokinetics</subject><subject>Methylphenidate - pharmacology</subject><subject>Nerve Tissue Proteins</subject><subject>Perception tests</subject><subject>Positron emission tomography</subject><subject>T tests</subject><subject>Time Factors</subject><subject>Tissue Distribution</subject><subject>Tomography, Emission-Computed</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAQxS0EKkvhjpAQUQ-ISxZPHH9JXFD5aKVKRaiIo-vYTjerxE5tB9j_niy7rCgHOI1G7_dGM_MQegp4CZiT16PXaSnJEuTcEyHuoQVgCSWrJb6PFhhXvBR1VT9Ej1JaY4wlFfgIHQkBTABeoK-fXa9zF3xadWPRuPzdOV98ShuzCil3w9Rrn8tzbyfjbHF9fdbdrE4K7W3xLox66LwrrqL2aQwxu1hcGjON2pvNY_Sg1X1yT_b1GH358P7q9Ky8uPx4fvr2ojS0IrlsjCYA0jIJlENlG6i4ZYRTqh0FzivJqQFbgaYWA7WtpI2zrLKGMdkySY7Rm93ccWoGZ43zOepejbEbdNyooDt1V_HdSt2Eb4oIIuvZ_nJvj-F2cimroUvG9fPVLkxJcUFqxgn7LwhU1DO6XejkL3AdpujnH6gKAwEpMZkhvINMDClF1x4WBqy2waptsEoSBVL9Cna2PP_z0INhn-Ssv9jrW-dv9e6EV_8mVDv1fXY_8ow-26HrlEM8sDUmkpKf0uTBcA</recordid><startdate>19960917</startdate><enddate>19960917</enddate><creator>Volkow, N. D.</creator><creator>G.-J. Wang</creator><creator>Fowler, J. S.</creator><creator>Gatley, S. J.</creator><creator>Y.-S. Ding</creator><creator>Logan, J.</creator><creator>Dewey, S. L.</creator><creator>Hitzemann, R.</creator><creator>Lieberman, J.</creator><general>National Academy of Sciences of the United States of America</general><general>National Acad Sciences</general><general>National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19960917</creationdate><title>Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy</title><author>Volkow, N. D. ; G.-J. Wang ; Fowler, J. S. ; Gatley, S. J. ; Y.-S. Ding ; Logan, J. ; Dewey, S. L. ; Hitzemann, R. ; Lieberman, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-bca3119d6915712db127d63755ae51772975c1d21a5d015df95bed62dc669f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Anxiety</topic><topic>Blood plasma</topic><topic>Blood Pressure - drug effects</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - drug effects</topic><topic>Brain - physiology</topic><topic>Carbon Radioisotopes</topic><topic>Carrier Proteins - drug effects</topic><topic>Carrier Proteins - metabolism</topic><topic>Central Nervous System Stimulants - pharmacokinetics</topic><topic>Central Nervous System Stimulants - pharmacology</topic><topic>Cerebellum</topic><topic>Cerebellum - diagnostic imaging</topic><topic>Cerebellum - drug effects</topic><topic>Cerebellum - physiology</topic><topic>Cocaine</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - physiology</topic><topic>Dopamine Plasma Membrane Transport Proteins</topic><topic>Dopamine Uptake Inhibitors - pharmacokinetics</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Dosage</topic><topic>Drug therapy</topic><topic>Emotions - drug effects</topic><topic>Emotions - physiology</topic><topic>Heart rate</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical research</topic><topic>Medications</topic><topic>Membrane Glycoproteins</topic><topic>Membrane Transport Proteins</topic><topic>Methylphenidate - pharmacokinetics</topic><topic>Methylphenidate - pharmacology</topic><topic>Nerve Tissue Proteins</topic><topic>Perception tests</topic><topic>Positron emission tomography</topic><topic>T tests</topic><topic>Time Factors</topic><topic>Tissue Distribution</topic><topic>Tomography, Emission-Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Volkow, N. D.</creatorcontrib><creatorcontrib>G.-J. Wang</creatorcontrib><creatorcontrib>Fowler, J. S.</creatorcontrib><creatorcontrib>Gatley, S. J.</creatorcontrib><creatorcontrib>Y.-S. Ding</creatorcontrib><creatorcontrib>Logan, J.</creatorcontrib><creatorcontrib>Dewey, S. L.</creatorcontrib><creatorcontrib>Hitzemann, R.</creatorcontrib><creatorcontrib>Lieberman, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Volkow, N. D.</au><au>G.-J. Wang</au><au>Fowler, J. S.</au><au>Gatley, S. J.</au><au>Y.-S. Ding</au><au>Logan, J.</au><au>Dewey, S. L.</au><au>Hitzemann, R.</au><au>Lieberman, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>1996-09-17</date><risdate>1996</risdate><volume>93</volume><issue>19</issue><spage>10388</spage><epage>10392</epage><pages>10388-10392</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>The ability of cocaine to inhibit the dopamine transporter (DAT) appears to be crucial for its reinforcing properties. The potential use of drugs that produce longlasting inhibition of the DAT as a mean of preventing the ``high'' and reducing drug-seeking behavior has become a major strategy in medication development. However, neither the relation between the high and DAT inhibition nor the ability to block the high by prior DAT blockade have ever been demonstrated. To evaluate if DAT could prevent the high induced by methylphenidate (MP), a drug which like cocaine inhibits the DAT, we compared the responses in eight nondrug-abusing subjects between the first and the second of two MP doses (0.375 mg/kg, i.v.) given 60 min apart. At 60 min the high from MP has returned to baseline, but 75-80% of the drug remains in brain. Positron-emission tomography and [$^{11}$C]d-threo-MP were used to estimate DAT occupancies at different times after MP. DAT inhibition by MP did not block or attenuate the high from a second dose of MP given 60 min later, despite a 80% residual transporter occupancy from the first dose. Furthermore some subjects did not perceive a high after single or repeated administration despite significant DAT blockade. These results indicate that DAT occupancy is not sufficient to account for the high, and that for DAT inhibitors to be therapeutically effective, occupancies &gt;80% may be required.</abstract><cop>United States</cop><pub>National Academy of Sciences of the United States of America</pub><pmid>8816810</pmid><doi>10.1073/pnas.93.19.10388</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8424
ispartof Proceedings of the National Academy of Sciences - PNAS, 1996-09, Vol.93 (19), p.10388-10392
issn 0027-8424
1091-6490
language eng
recordid cdi_proquest_miscellaneous_15843469
source Jstor Complete Legacy; MEDLINE; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects Adult
Anxiety
Blood plasma
Blood Pressure - drug effects
Brain - diagnostic imaging
Brain - drug effects
Brain - physiology
Carbon Radioisotopes
Carrier Proteins - drug effects
Carrier Proteins - metabolism
Central Nervous System Stimulants - pharmacokinetics
Central Nervous System Stimulants - pharmacology
Cerebellum
Cerebellum - diagnostic imaging
Cerebellum - drug effects
Cerebellum - physiology
Cocaine
Corpus Striatum - diagnostic imaging
Corpus Striatum - drug effects
Corpus Striatum - physiology
Dopamine Plasma Membrane Transport Proteins
Dopamine Uptake Inhibitors - pharmacokinetics
Dopamine Uptake Inhibitors - pharmacology
Dosage
Drug therapy
Emotions - drug effects
Emotions - physiology
Heart rate
Heart Rate - drug effects
Humans
Kinetics
Male
Medical research
Medications
Membrane Glycoproteins
Membrane Transport Proteins
Methylphenidate - pharmacokinetics
Methylphenidate - pharmacology
Nerve Tissue Proteins
Perception tests
Positron emission tomography
T tests
Time Factors
Tissue Distribution
Tomography, Emission-Computed
title Relationship between Psychostimulant-Induced ``High" and Dopamine Transporter Occupancy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A05%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20Psychostimulant-Induced%20%60%60High%22%20and%20Dopamine%20Transporter%20Occupancy&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Volkow,%20N.%20D.&rft.date=1996-09-17&rft.volume=93&rft.issue=19&rft.spage=10388&rft.epage=10392&rft.pages=10388-10392&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.93.19.10388&rft_dat=%3Cjstor_proqu%3E40395%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201319903&rft_id=info:pmid/8816810&rft_jstor_id=40395&rfr_iscdi=true